Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.41, $0.07 better than the analyst estimate of $0.34. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.47 billion.

GUIDANCE:

Boston Scientific sees Q3 2018 EPS of $0.33-$0.35, versus the consensus of $0.34. The company estimates sales for the third quarter of 2018 to be in a range of $2.380 to $2.420 billion, which versus the prior year period represents a growth range of approximately 7 to 9 percent on a reported basis and a growth range of approximately 7 to 8 percent on an organic basis, excluding the impact of foreign currency fluctuations.

Boston Scientific sees FY2018 EPS of $1.37-$1.41, versus the consensus of $1.39. The company now estimates revenue for the full year 2018 to be in a range of $9.800 to $9.880 billion (compared to prior guidance of $9.750 to $9.900 billion), which versus the prior year period represents a growth range of approximately 8 to 9 percent on a reported basis and growth of approximately 6 to 7 percent on an organic basis excluding the impact of foreign currency fluctuations and contribution of approximately 40 basis points from acquisitions

For earnings history and earnings-related data on Boston Scientific (BSX) click here.